Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats

Table 4 Effect of Doxorubicin (DOX) and AHE treatment on cardiac tissue antioxidant enzymes

Group	POD (U/min)	SOD (U/mg protein)	CAT (U/min)	QR (nM/min/mg protein)
Control	10.66 ± 0.538^b	1.146 ± 0.037^b	15.76 ± 0.118^b	137.5 ± 0.735^b
DOX	5.970 ± 0.560^a	0.7845 ± 0.027^a	9.025 ± 0.090^a	83.45 ± 0.416^a
AHE alone	10.92 ± 0.531^b	1.145 ± 0.049^b	15.66 ± 0.197^b	137.7 ± 0.392^b
DOX + AHE (200)	8.63 ± 0.363^a,b**	0.9799 ± 0.027^b*	12.87 ± 0.297^a,b,d	117.6 ± 0.652^a,b,d
DOX + AHE (400)	9.600 ± 0.3464^b	1.042 ± 0.025^b**	14.95 ± 0.216^b,c	131.0 ± 1.621^a**^,b,c
DOX + Sily	9.590 ± 0.3406^b	1.055 ± 0.053^b**	14.93 ± 0.256^b	130.4 ± 0.7148^a,b

Values expressed as mean ± SEM
^aSignificance at p < 0.0001 Vs. control group
^bSignificance at p < 0.0001 Vs. Doxorubicin (DOX) group
^cSignificance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group
^dSignificance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group
*, **Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin

ISSN: 2662-7671